First-in-Man, Randomised, Double-Blind, Placebo-Controlled, Single Dose Escalation Study of the Novel Compound 4SC-203 in Young Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2011
At a glance
- Drugs 4SC 203 (Primary)
- Indications Cancer
- Focus Adverse reactions; Biomarker
- 27 Sep 2011 Results presented at the 2011 European Multidisciplinary Cancer Congress.
- 19 Jan 2011 Results presented in a 4SC AG media release
- 12 Jan 2011 Actual end date (November 2010) added as reported by ClinicalTrials.gov.